设为首页|加入收藏|英文版

总体介绍

首页 > 广东省中医药科学院 > 总体介绍

类风湿关节炎临床与基础研究团队

2017/7/6 16:39:27字号:T|T

 

宗旨:利用现代科学方法和手段更好的去理解和探索类风湿关节炎的中医药理论,从而为这一难治性自身免疫疾病提供更优化的诊疗手段。

Aim of Team: To understand and further determine Chinese Medicine (CM) in the field of Rheumatoid Arthtitis (RA) by using Modern Methodology and Technique, and thus it may provide the better approaches for diagnosing and treating this refractory autoimmune disease.

 

主攻方向 Major Topics:

1. 治疗类风关的中药复方临床研究:

本团队首次提出“中药复方DMARDs”理念,并基于该学术理念创制治难治性类风关的中药复方制剂——化瘀通痹方。该方是在我团队使用“活血化瘀法”治疗类风湿关节炎20余年、进行了大量的基础和临床研究基础上,糅合了国医大师朱良春治痹学术思想和澳门学者刘良运用经方治痹经验,提炼而成。我们将该方与类风湿关节炎金标准药物甲氨蝶呤联用治疗难治性类风关,相对于西药方案(来氟米特联合甲氨蝶呤)具有更好的安全性和患者耐受性。现正开展大规模、多中心、随机对照临床研究深入观察进行疗效与安全性评价研究。

1.  Clinical Study for Chinese Herbal formula in treating Rheumatoid Arthritis

  Our team for the first time proposed the notion of “Chinese Medical formula DMARDs”, and subsequently created an special herbal formula, named “Huayu-Tongbi-Fang”, which is for therapy of refractory rheumatoid arthritis. By utilizing a Chinese Medicine strategy, “Huoxue-Huayu Fa (method of promoting blood circulation and removing blood-stasis)” , we have been treating the patients with RA for more than 20 years. The efficacy and safety are deem assured. For this Chinese Medicine strategy, we have done loads of basic and clinical research to clarify its efficacy and safety. Based on these work, we took up into academic thought of rheumatism master Zhu Liangchun in Chinese Medicine and the experience from Macao Scholar Liu Liang for applying Classical prescription of traditional Chinese Medicine into RA therapy. The herbal formula “Huayu-Tongbi Fang” was created thereof. Recently we have found that the modified therapeutic strategy, i.e. the combination of this herbal formula and methotrexate holds a better patient tolerance and even safer, as compared to the combination of leflunomide methotrexate in treating patients with RA. To further evaluate the efficacy and safety of this modified therapeutic strategy, a large scale, multi-center, randomized controlled clinical study is ongoing.

1. 基于组学技术的中药复方疗效机制研究:

随着系统生物学的发展,基因组学、代谢组学、表观遗传组学以及肠道微生态等组学相关的高通量测序技术成为阐述中药复方多靶点整体调节机制的有力工具。我们前期与华大基因和协和医院风湿科合作,基于肠道微生态阐述了类风关的发病机制,共同发表了Nature Medicine论文。我们将基于这一工作基础进一步对中药复方及中西医结合优化方案的干预调节机制进行阐述,从而与临床研究数据相结合全面构建基于化瘀通痹方的中西医结合优化方案的疗效与安全性评估数据库。

2. Study for Mechanisms underlying efficacy of herbal formula based on Omics technology.

The development of systemic biology has brought us many newly developed technologies. For example, the genomics, metabolic, epigenetic and gut microbiome high-throughput sequencing. This newly developed technology can be used as a very helpful tool for determining the underlying mechanisms of herbal formula efficacy. Previously we cooperated with Union Hospital and Beijing Genomics Institute to examine the role of gut microbiome in RA pathogenesis, and the study produced a publication in the journal of Nature Medicine. For now, we are still on the way in this area. The ongoing study will demonstrate the non-single targeted mechanisms for efficacy of our herbal formula and the modified therapeutic strategy through exploring the change of gut microbiome, which will be linked to data from clinical study to construct a huge data pool for evaluating the efficacy and safety of the modified therapeutic strategy associated with Huayu-Tongbi Fang.

3. 难治性类风关的中西医结合机制研究:

类风湿关节炎免疫与病理机制复杂,导致了其难治性和不可治愈性。要阐明其机制、探索更好的诊疗靶点,必须要进行多方合作,加强国际交流。我们将以血清阴性类风关为切入点与荷兰乌特勒支大学医学中心合作开展研究,着力研究诊断与鉴别诊断标志物以及中医证候生物标志物。

3. Basic research for refractory rheumatoid arthritis by Integrated Chinese and Western Medicine method.

  RA is a refractory and incurable disease, which is at least in part due to its complicated pathogenesis that is still largely unknown until now. Thus, a wide cooperation and more international communications could be much helpful for getting more knowledge about the pathogenesis of this refractory disease and developing fresh and efficiency targets of diagnosis and treatment. Under this background, we are now collaborating with University Medical Center Utrecht to conduct several researches on seronegative RA, which will be open a new way for discovery biomarkers of diagnosis, antidiastole and Chinese medical syndrome features of this disease.


团队负责人黄清春

Principle Investigator Huang Qingchun

主任医师,医学博士、博士后,博士研究生导师、博士后合作导师。广东省中医药学会风湿病专业委员会主任委员,世界中医药学会联合会中医药免疫专业委员会副会长兼副秘书长,中华中医药学会免疫分会副主委、风湿病分会常委。具有丰富的中西医结合风湿病临床经验,主持国家级及省部级课题10余项,发表中文核心期刊论文及SCI论文40余篇。

Huang Qinchun: MD, PhD, Chief physician. He got a postdoctoral experience and now is the mentor for PhD students and postdoctoral fellows. He is the chairman for Rheumatology branch of Guangdong Association of Chinese Medicine, vice chairman and deputy secretary general for Chinese Medical Immunology branch of World Federation of Chinese Medicine Society, vice chairman for Immunology branch and Standing Committee Member for Rheumatology branch of China Association of Chinese Medicine. He holds rich clinical experience in Rheumatology and hosts more than 10 national or provincial grants. Until now, he published more than 40 research articles (in Chinese or English) in Rheumatology field.

 

承担的主要研究课题 Grants

课题名称

任务来源

级别

负责人

经费

(万元)

类风湿关节炎的中医病证规律与综合治疗方案研究

国家科技支撑计划子课题

国家级

黄清春

21.5

从Cx43半通道探讨补肾强督法对强直性脊柱炎抑制骨化和改善骨质疏松作用的机制研究

国家自然科学基金委员会

国家级

黄清春

68

甘草酸对非小细胞肺癌血栓素相关通路的调节机制研究

国家自然科学基金委员会

国家级

黄闰月

23

中医药标准修订项目(皮肌炎和硬皮病)

国家中医药管理局

国家级

黄清春

50

盐酸青藤碱单体中药制剂质量标准提升核心技术研究及应用

子课题

湖南省战略性新兴产业项目协作单位

省部级

黄清春

 

50

基于microRNA的血清阴性RA诊断及证候血清标志物的研究

中国博士后科学基金特别资助项目

国家级

陈秀敏

 

15

基于miRNA研究关节型银屑病诊断及其证候的血清标志物

中国博士后科学基金

国家级

陈秀敏

5

基于类风湿关节炎“血瘀”病机的化瘀通痹方联合甲氨蝶呤形成中西医交融优化方案的临床疗效评价研究

广东省科技厅-广东省中医药科学院联合专项

省部级

黄清春

30

基于COX-2/TxA2通路与甘草有效成分甘草酸探讨类风湿关节炎优化治疗方案可行性的临床前研究

广东省科技厅-广东省中医药科学院联合专项

省部级

黄闰月

10

基于miRNA芯片技术的类风湿关节炎寒热证侯血清标志物的筛选与鉴定

广东省自然科学基金

省部级

黄清春

10

中西药物治疗类风湿性关节炎对肠微生态影响的比较研究

临床课题协作组

澳门科学技术发展基金

省部级

黄清春

14MOP

基于化瘀通痹方治疗类风湿关节炎的中西医结合优化方案临床疗效评价研究

广东省中医药科学院临床评价研究专项

校级

黄清春

25

类风湿关节炎特异性LincRNAs的表达研究

)广东省中医药科学院转化医学研究专项

校级

黄闰月

8

 

 

发表的主要学术论文 Selected Publications

论文

期刊

影响

因子

作者

通讯

作者

Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?

Oncotarget. October 20, 2015. DOI: 10.18632/oncotarget.6200

6.359

黄清春

黄闰月

An exploration of the role of microRNAs in Psoriasis: a systematic review of the literature.

Medicine (ISSN: 0025-7974), 2015 Aug;94(31):e1326.

5.732

黄闰月

卢传坚

Role of micro RNAs in the pathogenesis of rheumatoid arthritis: novel perspectives based on review of the literature.

Medicine (ISSN: 0025-7974), 2015 Aug;94(31):e1326.

5.732

陈秀敏

黄清春

黄闰月

The cyclooxygenase-2/thromboxane A2 pathway: a bridge from rheumatoid arthritis to lung cancer?

Cancer Lett. 2014 Nov 1;354(1):28-32.

5.016

黄清春

黄闰月

Determination of role of thromboxane A2 in rheumatoid arthritis.

Discov Med. 2015 Jan;19(102):23-32.

3.626

王茂杰

黄闰月

黄羽

Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis.

Evid Based Complement Alternat Med. 2015;2015:910376.

1.88

陈秀敏

黄闰月

黄清春

Role of cysteinerich angiogenic inducer 61 in fibroblastlike synovial cell proliferation and invasion in rheumatoid arthritis.

Mol Med Rep. 2015 Feb;11(2):917-23.

1.554

接力刚

黄清春

 

 





 



 


首页|网站地图|法律申明|友情链接|招聘信息|供应商管理|名老中医学术交流|中医健康管理|中医医案管理 |知识管理|在线考试